Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bank of Montreal — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Bank of Montreal trades at $174.17 (market cap $124.94B). The key difference: Bank of Montreal is far larger — about 27.8× ACADIA Pharmaceuticals Inc.'s market cap, and Bank of Montreal pays a 2.78% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BMO | |
|---|---|---|
Market Cap | $4.49B | $124.94B |
Sector | Health | Financials |
52-Week High | $28.06 | $178.25 |
52-Week Low | $20.06 | $110.44 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BMO trades at $178.25, up 2.37% today, with a bullish technical signal and strong analyst support. Recent earnings show a mixed record with a Q1 2026 miss but beats in prior quarters, while revenue and net income have grown steadily. The company maintains a solid dividend history and was recently recognized as Best Commercial Bank in Canada and the U.S. by World Finance Magazine (June 23, 2026).
The outlook is positive given earnings growth and strategic acquisitions, but risks include valuation above historical averages and sensitivity to interest rates. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism for continued performance amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
